Elan Corp Plc and Cambridge University together against Alzheimer’s and Parkinson’s disease
Elan Corp Plc has signed a deal with Cambridge University to establish a Research Centre there in Cambridge University focusing on work related to research for the treatment of Alzheimer’s and Parkinson’s disease, as reported by Dublin-headquartered biotech group.
Elan’s main research facility in San Francisco and it will spend $10 million dollar on the research center over the next five years and may extend the deal for further five years.
Researchers from both of both want to work on ways to change the working of proteins that are the possible cause of the spread of the neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease.
Dale Schenk, chief scientific officer at Elan, said,
This agreement is a natural next step in the existing working relationship between our scientists in South San Francisco and scientists at the University of Cambridge.
This collaborative effort complements our portfolio of programmes in neuroscience and supports the process of discovery which we believe may lead to a class of therapeutics that no one has thought possible before.